Publications

• SOHO State of the Art Updates and Next Questions | Choosing and Properly Using a JAK Inhibitor in Myelofibrosis.
  Clin Lymphoma Myeloma Leuk Volume: 25 Page(s): 226 - 239
  04/01/2025 Authors: Hochman MJ; Vale CA; Hunter AM
• Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib: A Phase 1b Randomized Clinical Trial.
  JAMA Oncol Volume: 11 Page(s): 28 - 35
  01/01/2025 Authors: Jabbour E; Oehler VG; Koller PB; Jamy O; Lomaia E; Hunter AM; Uspenskaya O; Samarina S; Mukherjee S; Cortes JE
• Perspectives on drug development in chronic myelomonocytic leukemia: changing the paradigm.
  Blood Volume: 144 Page(s): 1987 - 1992
  11/07/2024 Authors: Hunter AM; Patnaik MM; Itzykson R; Mesa R; Karanes C; Li Y; de Claro RA; Norsworthy KJ; Theoret M; Pulte E
• Advances with janus kinase inhibitors for the treatment of myeloproliferative neoplasms: an update of the literature.
  Expert Opin Pharmacother Volume: 25 Page(s): 1391 - 1404
  07/01/2024 Authors: Hunter AM; Bose P
• Choosing and Properly Using a JAK Inhibitor in Myelofibrosis
  CLINICAL LYMPHOMA MYELOMA & LEUKEMIA Volume: 23 Page(s): S86 - S87
  09/01/2023 Authors: Vale CA; Hunter AM
• Bromodomain and Extra-Terminal (BET) Inhibitor INCB057643 (LIMBER-103) in Patients With Relapsed or Refractory Myelofibrosis (R/R MF) and Other Advanced Myeloid Neoplasms: A Phase I Study
  Volume: 23 Page(s): S403 - S404
  09/01/2023 Authors: Watts J; Hunter A; Iurlo A; Xicoy B; Palandri F; Reeves B; Vannucchi A; Bose P; Diaz R; Halpern A
• Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS).
  Blood Cancer J Volume: 12 Page(s): 153
  11/15/2022 Authors: Brunner AM; Gavralidis A; Ali NA; Hunter A; Komrokji R; Zeidan A; Sallman DA
• Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis.
  Blood Adv Volume: 6 Page(s): 5750 - 5762
  11/08/2022 Authors: Reiter A; Schwaab J; DeAngelo DJ; Gotlib J; Deininger MW; Pettit KM; Alvarez-Twose I; Vannucchi AM; Panse J; Platzbecker U
• Progenitor Hierarchy of Chronic Myelomonocytic Leukemia Identifies Inflammatory Monocytic-Biased Trajectory Linked to Worse Outcomes.
  Blood Cancer Discov Volume: 3 Page(s): 536 - 553
  11/02/2022 Authors: Ferrall-Fairbanks MC; Dhawan A; Johnson B; Newman H; Volpe V; Letson C; Ball M; Hunter AM; Balasis ME; Kruer T
• Differential prognostic impact of IDH1 and IDH2 mutations in chronic myelomonocytic leukemia.
  Leukemia Volume: 36 Page(s): 1693 - 1696
  06/01/2022 Authors: Walsh C; Hunter A; Lasho T; Finke C; Ketterling R; Komrokji R; Tefferi A; Mangaonkar A; Howard M; Gangat N
• Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts.
  Leukemia Volume: 36 Page(s): 1189 - 1192
  04/01/2022 Authors: Swoboda DM; Kanagal-Shamanna R; Brunner AM; Cluzeau T; Chan O; Al Ali N; Montalban-Bravo G; Gesiotto QJ; Gavralidis A; Hunter AM
• Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation.
  Blood Volume: 139 Page(s): 1066 - 1079
  02/17/2022 Authors: You X; Liu F; Binder M; Vedder A; Lasho T; Wen Z; Gao X; Flietner E; Rajagopalan A; Zhou Y
• Integrated Human and Murine Clinical Study Establishes Clinical Efficacy of Ruxolitinib in Chronic Myelomonocytic Leukemia.
  Clin Cancer Res Volume: 27 Page(s): 6095 - 6105
  11/15/2021 Authors: Hunter AM; Newman H; Dezern AE; Steensma DP; Niyongere S; Roboz GJ; Mo Q; Chan O; Gerds A; Sallman DA
• Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy.
  Leuk Res Volume: 109 Page(s): 106640
  10/01/2021 Authors: Hunter AM; Al Ali N; Mai A; Shah S; Swoboda DM; Kuykendall A; Talati C; Sweet KL; Sallman DA; Lancet JE
• Genomic Landscape and Risk Stratification in Chronic Myelomonocytic Leukemia.
  Curr Hematol Malig Rep Volume: 16 Page(s): 247 - 255
  06/01/2021 Authors: Hunter A; Padron E
• Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis.
  Blood Cancer J Volume: 11 Page(s): 52
  03/06/2021 Authors: Kanagal-Shamanna R; Montalban-Bravo G; Katsonis P; Sasaki K; Class CA; Jabbour E; Sallman D; Hunter AM; Benton C; Chien KS
• Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes.
  Blood Adv Volume: 5 Page(s): 1017 - 1028
  02/23/2021 Authors: Hunter AM; Komrokji RS; Yun S; Al Ali N; Chan O; Song J; Hussaini M; Talati C; Sweet KL; Lancet JE
• Outcomes of patients with chronic myelomonocytic leukaemia treated with non-curative therapies: a retrospective cohort study.
  Lancet Haematol Volume: 8 Page(s): e135 - e148
  02/01/2021 Authors: Pleyer L; Leisch M; Kourakli A; Padron E; Maciejewski JP; Xicoy Cirici B; Kaivers J; Ungerstedt J; Heibl S; Patiou P
• Molecular genetics of MDS/MPN overlap syndromes.
  Best Pract Res Clin Haematol Volume: 33 Page(s): 101195
  09/01/2020 Authors: Hunter AM; Padron E
• Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
  Leukemia Volume: 34 Page(s): 1407 - 1421
  05/01/2020 Authors: Coltro G; Mangaonkar AA; Lasho TL; Finke CM; Pophali P; Carr R; Gangat N; Binder M; Pardanani A; Fernandez-Zapico M
• Targeting TP53 Mutations in Myelodysplastic Syndromes.
  Hematol Oncol Clin North Am Volume: 34 Page(s): 421 - 440
  04/01/2020 Authors: Hunter AM; Sallman DA
• Current status and new treatment approaches in TP53 mutated AML.
  Best Pract Res Clin Haematol Volume: 32 Page(s): 134 - 144
  06/01/2019 Authors: Hunter AM; Sallman DA
• Current Management and Recent Advances in the Treatment of Chronic Myelomonocytic Leukemia.
  Curr Treat Options Oncol Volume: 19 Page(s): 67
  10/27/2018 Authors: Hunter AM; Zhang L; Padron E
• Hemgolobin S-C Disease at the Emory University Georgia Comprehensive Sickle Cell Center at Grady Health System
  Volume: 128
  12/02/2016 Authors: Hunter A; Fasano RM; Eckman JR; McLemore ML; El Rassi F